NCT05610735View on ClinicalTrials.gov

Combination Therapy for Recurrent Ovarian Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

September 25, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2027

Conditions
Recurrent Ovarian Cancer
Interventions
DRUG

DOXIL

DOXIL will be administered IV as 40 mg/m2 IV every four weeks for 4 cycles or until disease progression and/or unacceptable toxicity, whichever comes first to a maximum of 10 cycles.

DRUG

Withaferin A

Ashwagandha in the form of tablets will be administered orally on daily basis.

DRUG

Ashwagandha

Administered orally on daily basis twice a day

DRUG

Combination of ASWD and DOXIL

DOXIL administered IV once every four weeks. ASWD administered orally on daily basis, twice a day.

Trial Locations (1)

40202

RECRUITING

UofL Health Brown Cancer Center, Louisville

All Listed Sponsors
collaborator

University of Louisville Health Care

UNKNOWN

lead

Sham Sunder Kakar

OTHER